Beijing, Aug 26, 2026 — China’s Center for Drug Evaluation (CDE) released draft technical guidelines for clinical research on drug concentration-QTc (C-QTc) relationships, opening a one-month public comment period to standardize cardiac safety assessments for innovative medicines.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Center for Drug Evaluation (CDE), National Medical Products Administration |
| Document | Draft Technical Guidelines for Clinical Research of Drug Concentration QTc |
| Scope | C-QTc clinical studies and data analysis for cardiac safety evaluation |
| Target drugs | Innovative medicines requiring cardiac safety profiling |
| Comment deadline | One month from publication |
| Contacts | Wang Yuzhu (wangyzh@cde.org.cn); Ma Jingyi (majy@cde.org.cn) |
Technical Context
The draft guidelines address concentration-QTc (C-QTc) modeling, a statistical approach used to evaluate whether a drug prolongs the corrected QT interval in an exposure-dependent manner. C-QTc analysis is increasingly favored as an alternative or complement to traditional thorough QT (TQT) studies under ICH E14 frameworks, allowing sponsors to integrate cardiac safety assessment into early-phase trials rather than conducting standalone studies.
Market Impact Analysis
The guideline marks a significant step in aligning China’s cardiac safety evaluation standards with international ICH E14 Q&A updates. For pharmaceutical developers, particularly those in oncology, central nervous system, and infectious disease pipelines where QT prolongation is a known class risk, the document provides a regulatory pathway to use C-QTc modeling as primary evidence for QT liability assessment. This could reduce clinical development timelines and costs by eliminating the need for separate TQT studies when robust exposure-response data is available.
The one-month comment window suggests CDE is moving quickly to finalize the guidance, reflecting urgency to keep pace with global regulatory convergence on cardiac safety methodologies. Domestic and multinational sponsors with pending new drug applications in China should review the draft closely, as the final version is likely to influence trial design for Phase I and Phase II studies currently in planning.
Forward-Looking Statement
Industry experts expect the finalized guidelines to be published by late 2026 or early 2027, following the comment period and potential revision. The adoption of C-QTc-centric guidance positions China to accept modeling-based cardiac safety waivers more routinely, potentially accelerating approvals for drugs in therapeutic areas where QT effects have historically triggered regulatory delays. Companies are advised to prepare C-QTc analysis capabilities—either internally or through specialized biostatistics contract research organizations—to align with the forthcoming mandatory standards.-China Health Reform Pulse
For detailed implementation guidelines and the full list of approved products, refer to the official announcements from the Guangdong Provincial Medical Device Exchange Center.
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/77085aae69c2d59b829839cf7377f107